

CLAIMS AMENDMENTS

Please cancel Claims 22, 38, 43 and 48, without prejudice.

Please amend the claims as follows:

Claim 1-20 (Canceled)

Claim 21 (Previously presented) A method of inhibiting the expression of mammalian KSR comprising contacting cells which express KSR with an effective amount of an antisense oligonucleotide comprising a sequence substantially complementary to SEQ ID NO: 5, wherein the oligonucleotide is from about 8 to about 50 nucleotides in length.

Claim 22 (Canceled)

Claim 23 (Previously presented) A method of treating a hyperproliferative condition associated with the expression of gf-Ras or heightened expression of Ras in a mammal comprising administering to said mammal a therapeutically effective amount of an antisense oligonucleotide comprising a sequence substantially complementary to SEQ ID NO: 5, wherein the oligonucleotide is from about 8 to about 50 nucleotides in length.

Claim 24 (Canceled)

Claim 25 (Currently amended) A method of treating a hyperproliferative condition associated with the expression of gf-Ras or heightened expression of Ras in a mammal comprising expressing in said mammal a therapeutically effective amount of an antisense oligonucleotide comprising a sequence substantially complementary to SEQ ID NO: 5, wherein the oligonucleotide is from about 8 to about 50 nucleotides in length.

Claim 26 (Currently amended) A method of treating or inhibiting the progression of cancer in a mammal comprising administering to a mammal a therapeutically effective amount of an antisense oligonucleotide comprising a sequence substantially complementary to SEQ ID NO: 5,

wherein the oligonucleotide is from about 8 to about 50 nucleotides in length.

Claim 27 (Previously presented) The method of claim 26, wherein said cancer is selected from the group of pancreatic cancer, lung cancer, skin cancer, urinary tract cancer, bladder cancer, liver cancer, thyroid cancer, colon cancer, intestinal cancer, leukemia, lymphoma, neuroblastoma, head and neck cancer, breast cancer, ovarian cancer, stomach cancer, esophageal cancer and prostate cancer.

Claim 28-30 (Canceled)

Claim 31 (Previously presented) A method of claim 21, wherein the oligonucleotide comprises a sequence that is 100% complementary to SEQ ID NO: 5, and the oligonucleotide is 18 to about 50 nucleotides in length.

Claim 32 (Previously presented) A method of claim 21, wherein the oligonucleotide comprises a modified backbone.

Claim 33 (Previously presented) A method of claim 21, wherein the oligonucleotide comprises at least one phosphorothioate linkage.

Claim 34 (Previously presented) A method of claim 21, wherein the oligonucleotide is 15-25 nucleotides in length.

Claim 35 (Previously presented) A method of claim 34, wherein the oligonucleotide is a phosphorothioate deoxynucleotide.

Claim 36 (Previously presented) A method of claim 21, wherein the oligonucleotide is 18 nucleotides in length.

Claim 37 (Previously presented) A method of claim 21, wherein the oligonucleotide is a phosphorothioate deoxynucleotide.

Claim 38 (Canceled)

Claim 39 (Previously presented) A method of claim 23, wherein the oligonucleotide comprises a sequence that is 100% complementary to SEQ ID NO: 5, and the oligonucleotide is 18 to about 50 nucleotides in length.

Claim 40 (Previously presented) A method of claim 23, wherein the oligonucleotide comprises at least one phosphorothioate linkage.

Claim 41 (Previously presented) A method of claim 23, wherein the oligonucleotide is 15-25 nucleotides in length.

Claim 42 (Previously presented) A method of claim 23, wherein the oligonucleotide is a phosphorothioate deoxynucleotide.

Claim 43 (Canceled)

Claim 44 (Previously presented) A method of claim 25, wherein the oligonucleotide comprises a sequence that is 100% complementary to SEQ ID NO: 5, and the oligonucleotide is 18 to about 50 nucleotides in length.

Claim 45 (Previously presented) A method of claim 25, wherein the oligonucleotide comprises at least one phosphorothioate linkage.

Claim 46 (Previously presented) A method of claim 25, wherein the oligonucleotide is 15-25 nucleotides in length.

Claim 47 (Previously presented) A method of claim 25, wherein the oligonucleotide is a phosphorothioate deoxynucleotide.

Claim 48 (Canceled)

Claim 49 (Previously presented) A method of claim 26, wherein the oligonucleotide comprises a sequence that is 100% complementary to SEQ ID NO: 5, and the oligonucleotide is 18 to about 50 nucleotides in length.

Claim 50 (Previously presented) A method of claim 26, wherein the oligonucleotide comprises at least one phosphorothioate linkage.

Claim 51 (Previously presented) A method of claim 26, wherein the oligonucleotide is 15-25 nucleotides in length.

Claim 52 (Previously presented) A method of claim 26, wherein the oligonucleotide is a phosphorothioate deoxynucleotide.

Claim 53 (Previously presented) A method of claim 27, wherein the cancer is pancreatic cancer.

Claim 54 (Previously presented) A method of claim 27, wherein the cancer is lung cancer.

Claim 55 (New) A method of claim 31, wherein the oligonucleotide has a sequence of SEQ ID NO: 8.

Claim 56 (New) A method of claim 39, wherein the oligonucleotide has a sequence of SEQ ID NO: 8.

Claim 57 (New) A method of claim 44, wherein the oligonucleotide has a sequence of SEQ ID NO: 8.

Claim 58 (New) A method of claim 49, wherein the oligonucleotide has a sequence of SEQ ID NO: 8.